Clinical Trial Update: A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase I study to evaluate safety and pharmacokinetics of a single subcutaneous dose of SHR-1894 in healthy subjects; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatitis

Drugs mentioned

• SHR-1894

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Dermatitis | Phase 1 | Status: RECRUITING